At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 862 enrolled
Drug / intervention
Symbicort (Budesonide/Formoterol)drug
Likely dose
Symbicort (Budesonide/Formoterol) 4.5 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA
In Brief
A Phase 4 clinical trial evaluating Symbicort (Budesonide/Formoterol) for Asthma. Completed, enrolled 862 participants across 35 sites in 5 countries.
Detailed Summary
The purpose of this study is to compare whether Symbicort Maintenance \& Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesChina, India, Indonesia, Taiwan, Thailand
Collaborators--
Timeline
Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2009
First PostedJul 2009
Primary CompletionAug 2010
TodayJul 2026
First PostedJul 15, 2009
Enrollment StartJul 1, 2009
Primary CompletionAug 1, 2010
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 17.0 years ago
Interventions
Symbicort (Budesonide/Formoterol)drug
Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms